New cancer drug combo enters human trials for Tough-to-Treat tumors
NCT ID NCT05405595
Summary
This study is testing a new drug called ADG126 in combination with an existing immunotherapy (pembrolizumab) for people with advanced solid tumors that have spread. The main goals are to find the safest and most effective dose and to see if the combination can help control the cancer. It will enroll about 186 adults whose cancer has progressed despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
Contact
Contact
-
CHA Bundang Medical Center, CHA university
RECRUITINGSeongnam, Gyeonggido, 13496, South Korea
Contact
Contact
-
Chungbuk National University Hospital
RECRUITINGCheongju-si, North Chungcheong, 28644, South Korea
Contact
Contact
-
City of Hope National Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact
Contact
-
City of Hope Orange County
RECRUITINGIrvine, California, 92618, United States
Contact
-
Dong -A University Hospital
TERMINATEDSeogu, Busan Gwangyeogsi, 49201, South Korea
-
Florida cancer specialist/Sarah Cannon Research Institute
ACTIVE_NOT_RECRUITINGSarasota, Florida, 34232, United States
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
Contact
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, China
Contact
-
Hong Kong Humanity & Health Clinical Trial Center
RECRUITINGHong Kong, Hong Kong, China
Contact
-
Honor Health Research Institute
RECRUITINGScottsdale, Arizona, 85251, United States
Contact
-
KangBuk Samsung Hospital
TERMINATEDSeoul, 03081, South Korea
-
Keimyung University Dongsan Hospital
TERMINATEDDaegu, 41931, South Korea
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact
-
Prince of Wales Hospital
RECRUITINGHong Kong, Hong Kong, China
Contact
-
Samsung Medical Center
RECRUITINGSeoul, Seoul Teugbyeolsi, 06351, South Korea
Contact
Contact
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
Contact
Contact
-
Severance Hospital Yonsei University Health System
RECRUITINGSeoul, 3722, South Korea
Contact
Contact
-
SunYat-Sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact
-
The Catholic University of Korea Street. Vincent Hospital
TERMINATEDSuwon, Gyeonggido, 16247, South Korea
-
The Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195-0001, United States
Contact
Conditions
Explore the condition pages connected to this study.